Medivir AB announced the company plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma.
Medivir AB announced the company plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma.